“False positive” urine pregnancy test results after successful medication abortion



      To examine the proportion of high-sensitivity urine pregnancy test (HSPT) results that were positive by time after successful medication abortion.

      Study design

      We used data from an ongoing study that provides mifepristone and misoprostol for medication abortion by direct-to-patient telemedicine and mail. Providers evaluated abortion outcomes by patient interview and clinical tests per clinical judgment and participant preference. We identified all participants enrolled July 2016 to September, 2020 who had an HSPT result and no indication of viable pregnancy after treatment. We used logistic regression to examine the association between the timing of the initial post-treatment HSPT, gestational age, and the proportion of HSPTs that gave a positive result.


      Of the 472 participants in our analysis, 88 (19%) had positive initial HSPTs. The proportions that were positive at ≤20 days, 21 to 27 days, 28 to 34 days, and ≥35 days after mifepristone ingestion was 14 of 29 (48%), 15 of 58 (26%), 49 of 258 (19%), and 10 of 127 (8%), respectively (p < 0.001). Gestational age at mifepristone ingestion was not significantly related to positive HSPT results (p = 0.28). Multivariable logistic regression confirmed both findings and did not identify a statistically significant interaction between these variables. In the 67 participants who relied solely on further HSPTs to confirm abortion outcome, the median interval between the initial positive test and first negative test was 14 days.


      The proportion of participants with positive HSPTs declined with time after successful medication abortion. However, nearly one-fifth of participants with complete abortion had positive tests 4 weeks after treatment.


      HSPTs provide an inexpensive, convenient option for confirming success of medication abortion at home. However, a substantial minority of patients without ongoing pregnancy have positive HSPT results. Development of a symptom-based strategy for medication abortion outcome assessment without any confirmatory tests should be a priority.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Upadhyay UD
        • Schroeder R
        • Roberts SCM.
        Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19.
        Contracept X. 2020; 2100049
        • Pocius KD
        • Maurer R
        • Fortin J
        • Goldberg AB
        • Bartz D.
        Early serum human chorionic gonadotropin (hCG) trends after medication abortion.
        Contraception. 2015; 91: 503-506
        • Pocius KD
        • Bartz D
        • Maurer R
        • Stenquist A
        • Fortin J
        • Goldberg AB.
        Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: a prospective study.
        Contraception. 2017; 95: 263-268
        • Fiala C
        • Safar P
        • Bygdeman M
        • Gemzell-Danielsson K.
        Verifying the effectiveness of medical abortion; ultrasound versus hCG testing.
        Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195
        • Honkanen H
        • Ranta S
        • Ylikorkala O
        • Heikinheimo O.
        The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy.
        Hum Reprod. 2002; 17: 2315-2319
        • Walker K
        • Schaff E
        • Fielding S
        • Fuller L.
        Monitoring serum chorionic gonadotropin levels after mifepristone abortion.
        Contraception. 2001; 64: 271-273
        • National Abortion Federation
        Clinical policy guidelines.
        Washington DC: National Abortion Federation, 2020
        • Raymond EG
        • Grossman D
        • Mark A
        • Upadhyay UD
        • Dean G
        • Creinin MD
        • et al.
        Commentary: No-test medication abortion: A sample protocol for increasing access during a pandemic and beyond.
        Contraception. 2020; 101: 361-366
        • Creinin MD
        • Grossman DA.
        Medication abortion up to 70 days of gestation: ACOG Practice Bulletin, Number 225.
        Obstet Gynecol. 2020; 136: e31-e47
        • Perriera LK
        • Reeves MF
        • Chen BA
        • Hohmann HL
        • Hayes J
        • Creinin MD.
        Feasibility of telephone follow-up after medical abortion.
        Contraception. 2010; 81: 143-149
        • Chen MJ
        • Rounds KM
        • Creinin MD
        • Cansino C
        • Hou MY.
        Comparing office and telephone follow-up after medical abortion.
        Contraception. 2016; 94: 122-126
        • Raymond E
        • Chong E
        • Winikoff B
        • Platais I
        • Mary M
        • Lotarevich T
        • et al.
        TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
        Contraception. 2019; 100: 173-177
        • Bastian LA
        • Nanda K
        • Hasselblad V
        • Simel DL.
        Diagnostic efficiency of home pregnancy test kits. A meta-analysis.
        Arch Fam Med. 1998; 7: 465-469
        • Boxer J
        • Weddell S
        • Broomhead D
        • Hogg C
        • Johnson S.
        Home pregnancy tests in the hands of the intended user.
        J Immunoassay Immunochem. 2019; 40: 642-652
        • Raymond EG
        • Shochet T
        • Bracken H.
        Low-sensitivity urine pregnancy testing to assess medical abortion outcome: a systematic review.
        Contraception. 2018; 98: 30-35
        • Chen MJ
        • Creinin MD.
        Mifepristone with buccal misoprostol for medical abortion: a systematic review.
        Obstet Gynecol. 2015; 126: 12-21
        • Jackson AV
        • Dayananda I
        • Fortin JM
        • Fitzmaurice G
        • Goldberg AB.
        Can women accurately assess the outcome of medical abortion based on symptoms alone?.
        Contraception. 2012; 85: 192-197
        • Harper C
        • Ellertson C
        • Winikoff B.
        Could American women use mifepristone-misoprostol pills safely with less medical supervision?.
        Contraception. 2002; 65: 133-142
        • Raymond EG
        • Tan YL
        • Grant M
        • Benavides E
        • Reis M
        • Sacks DN
        • et al.
        Self-assessment of medical abortion outcome using symptoms and home pregnancy testing.
        Contraception. 2018; 97: 324-328